Pfizer Inc. $PFE Shares Sold by Seizert Capital Partners LLC

Seizert Capital Partners LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 71.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 41,123 shares of the biopharmaceutical company’s stock after selling 102,174 shares during the period. Seizert Capital Partners LLC’s holdings in Pfizer were worth $1,024,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. State Street Corp grew its holdings in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp grew its holdings in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC grew its holdings in Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after purchasing an additional 897,786 shares during the period. Finally, Legal & General Group Plc grew its holdings in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock valued at $1,063,565,000 after purchasing an additional 3,296,415 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Guggenheim boosted their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. Finally, Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.74.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval: Pfizer and Arvinas won FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind therapy for ESR1‑mutated advanced breast cancer — a commercial and pipeline catalyst that can expand oncology revenue and investor expectations. Read More.
• Positive Sentiment: Analyst support: Guggenheim reaffirmed a Buy and a $36 price target ahead of Q1, highlighting upcoming pipeline catalysts and raising expectations for revenue and guidance. Read More.
• Positive Sentiment: Analysts bullish on pipeline: Q1 previews emphasize a robust non‑COVID portfolio and investor focus on obesity and oncology programs — key drivers that could lift guidance and sentiment if management commentary is constructive. Read More.
• Positive Sentiment: Relative positioning vs. peers: Coverage argues Pfizer is a post‑COVID winner versus Moderna thanks to diversification and a push into obesity drugs — narrative supports defensive, income‑oriented investor interest. Read More.
• Neutral Sentiment: Dividend/income focus: Several pieces highlight Pfizer’s attractive yield and option strategies for income generation ahead of earnings — this sustains interest from income investors but raises sensitivity to dividend safety and payout guidance. Read More.
• Neutral Sentiment: Q1 earnings watch: Preview and “what to look for” pieces flag EPS/revenue estimates, obesity program updates and guidance commentary as the immediate drivers; results/guidance will likely dictate short‑term direction. Read More.
• Neutral Sentiment: Macro headwind: Major indexes dipped amid rising oil and geopolitical tension — broader market weakness can pressure cyclicals and large caps like Pfizer even if company‑specific news is positive. Read More.
• Negative Sentiment: Media skepticism on yield/valuation: Commentators including Jim Cramer warned that Pfizer’s yield isn’t compelling enough relative to bonds and questioned upside, which can deter income/value buyers. Read More.
• Negative Sentiment: Valuation/long‑term skepticism: Opinion pieces label the stock “priced like dead money,” underscoring investor concern about limited capital‑gains potential despite high yield — a headwind for growth‑oriented flows. Read More.

Pfizer Price Performance

PFE opened at $26.31 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $21.97 and a 52-week high of $28.75. The company has a 50 day moving average of $27.17 and a two-hundred day moving average of $26.11. The company has a market cap of $149.61 billion, a P/E ratio of 19.35 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer’s payout ratio is currently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.